Accessibility Tools
Call the office at 561 483-8840 for pricing
  • Gastric Sleeve
  • Gastric Bypass
  • Revisional Surgery
  • Please call the office for pricing

Bariatric Surgery Cures Diabetes Research and Findings

Bariatric Surgery Cures Diabetes Research and Findings
Bariatric Surgery Cures Diabetes Research and Findings

At 6 years of follow-up data, bariatric surgical “cures” of type 2 diabetes are holding steady in a single-center series of 217 patients. “We see sustained weight loss, particularly in Roux-enY gastric bypass patients, 5-9 years after surgery.” Diabetes remitted in 50% of patients, according to Dr. Stacy A. Brethauer, an ACS Fellow of the Cleveland Clinic. “Bariatric surgery also achieved excellent long-term control of other cardiovascular risk factors; and diabetic nephropathy improved or stabilized.
Of 217 obese type 2 diabetic patients followed for a median of 6 years after bariatric surgery, 24% have been “cured.” They have maintained a hemoglobin A1c level below 6% and fasting blood glucose values below 100 mg/dL for more than 5 years while off all antidiabetic medications, Dr. Brethauer reported at the annual meeting of the American Surgical Association.
Another 26% of patients have had partial remissions, meaning they maintained target HbA1c and fasting blood glucose levels off antidiabetic medications for more than 1 year but less than 5 years. In addition, 34% of patients were classified as “improved” based upon an absolute 1% or more reduction in HbA1c, a drop in fasting blood glucose in excess of 25 mg/dL, and a halving in the dose of antidiabetic medication for at least 1 year. Diabetes recurred in 19% of subjects. Recurrence was defined as a return to an HbA1c of 6.5% or more or a fasting blood glucose level of at least 126 mg/dL.
The overall study population improved from a mean body mass index of 49 kg/m2 before surgery to 37 kg/m2 at 6 years after surgery. The mean HbA1c was 7.5% at baseline and 6.5% at 6 years. Fasting blood glucose at 6 years was a mean of 41.6 mg/dL lower than it was before surgery. LDL cholesterol levels were down by a mean of 10.1 mg/dL and HDL levels were up by 9.8 mg/dL. Systolic blood pressure was reduced by a mean of 10.9 mm Hg, with diastolic blood pressure down by 3.2 mm Hg at 6 years after surgery.
Preoperatively, 95% of patients were on antidiabetes medications; at 6 years after bariatric surgery, 54% were not on any antidiabetes drugs.
At baseline, 3% of subjects met all three key metabolic goals for diabetic patients as defined by the American Diabetes Association: an HbA1c below 7%; blood pressure below 130/80 mm Hg; and an LDL level below 100 mg/dL. At 6 years after surgery, 28% of patients met these goals. That result is particularly impressive in light of other studies that indicate 13% of the U.S. diabetic population as a whole meet all three goals.
Of 40 gastric bypass recipients known to have a normal urinary albumin-to-creatinine ratio preoperatively, only 1 developed macroalbuminuria and 1 microalbuminuria during a mean of 6 years’ follow-up.
Albuminuria regressed in 10 of the 19 gastric bypass recipients known to have the disorder at baseline. Albuminuria remained stable in the other 9 patients over the course of 6 years. Mean excess weight loss at 1-2 years of follow-up was 61% in the 162 patients who underwent gastric bypass, 50% in the 23 with sleeve gastrectomy, and 30% in patients who had a gastric banding procedure.
In a multivariate analysis adjusted for baseline clinical characteristics, the significant predictors of diabetes remission following bariatric surgery were greater excess weight loss, preoperative diabetes duration of less than 5 years, and having a gastric bypass operation rather than sleeve gastrectomy or a gastric banding procedure.
Dr. Brethauer said this study, taken together with the findings of an earlier randomized clinical trial by the same investigators (N. Engl. J. Med. 2012;366:1567-76), conveys a clear message: “Bariatric surgery can induce a significant and sustainable remission of type 2 diabetes and other metabolic risk factors in obese patients and should be considered early in the course of the disease.”
Discussant Dr. Walter J. Pories called the study “a really important contribution.” He added that it’s high time for nonsurgeons to get on board. “One would have thought our medical colleagues would be ecstatic at the news that an operation on the gut – a safe procedure that can be done in about an hour – could produce full and durable remission of diabetes with complete prevention of amputations, blindness, and kidney failure. But that hasn’t been the case. All we’ve heard are cries for more and more evidence,” said Dr. Pories, professor of surgery at East Carolina University, Greenville, N.C. He said that Dr. Brethauer and his colleagues set the bar too high in requiring a sustained HbA1c below 6% as the definition of disease cure when the American Diabetes Association uses a figure of 7%. If the investigators had accepted the ADA metric, their combined cure/partial remission rate would have been considerably greater than the 50% figure they reported.
Dr. Brethauer replied that: “When we raise this issue of ‘cure,’ which is still quite controversial and somewhat provocative, particularly with our endocrinology colleagues, I think we have to find the strictest and most conservative criteria that we can.” “It’s a major paradigm shift for our endocrinology colleagues to accept. I think it’s going to take a generation of endocrinologists before it’s embraced,” he explained. He serves as a consultant to Ethicon Endosurgery and Apollo Endosurgery.
The study will be published in an upcoming issue of the Annals of Surgery.

This article was taken from the ACS Surgery News VOL. 9 • NO. 7 • JULY 2013